FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Medinol Gets OK on Latest Drug-Eluting Stent

FDA approves Medinols EluNIR-PERL drug-eluting stent for treating coronary artery disease.

latest-news-card-1
Medical Devices

Denti.AI Dental Imaging Cleared

FDA clears a Denti.AI 510(k) for its Denti.AI Detect, which is described as a state-of-the-art imaging solution engineered to aid dental professionals...

latest-news-card-1
Human Drugs

FDA Decision on Florida Drug Imports Delayed: Report

Florida officials ask a federal court to give FDA a bit longer to decide whether to approve a state plan to import some drugs from Canada for use in g...

latest-news-card-1
Human Drugs

Akebia Refiles Kidney Disease NDA

FDA accepts for review an Akebia Therapeutics NDA resubmission for vadadustat for treating anemia due to chronic kidney disease in adult patients on d...

latest-news-card-1
Human Drugs

Positive Results from BioXcel Data Audit

BioXcel Therapeutics says an independent data integrity audit of a TRANQUILITY II clinical trial site that was the subject of an FDA form FDA-483 repo...

latest-news-card-1
Human Drugs

Califf Positive on Visit to India

FDA commissioner Robert Califf posts a positive report on his recent visit to India and the work he says that the countrys government and drug industr...

latest-news-card-1
Human Drugs

Dermatologic Corticosteroid BE Guidance

FDA publishes a draft guidance to assist ANDA applicants in demonstrating the bioequivalence of topical corticosteroids.

latest-news-card-1

FDA Approves New Tibsovo Indication

FDA approves a new indication for Servier Pharmaceuticals Tibsovo to treat adults with some myelodysplastic syndromes as detected by an Abbott compani...

latest-news-card-1
Human Drugs

UCB Farchim FDA-483 Released

FDA releases the form FDA-483 with four observations from an inspection at Switzerlands UCB Farchim drug manufacturing facility.

latest-news-card-1

FDA Changes Off-Label Approach: Attorney

Hyman, Phelps & McNamara attorney Dara Levy says FDA is taking a new approach to off-label presentations in a new draft guidance.